Inclusion Criteria:

          1. Subject is willing and able to provide written informed consent for the study prior to
             the performance of any study-specific procedures

          2. Subject is a male or female subject ≥18 years of age at the time of consent

          3. Subject must have an ECOG PS ≤ 1

          4. Subject must have histologically or cytologically confirmed advanced or metastatic
             solid tumor

          5. Subjects who are refractory to FDA-approved, standard therapy or for which standard or
             curative therapy does not exist or is not considered sufficient or appropriate by the
             patient or Investigator

          6. Subject must have radiographically measurable or evaluable disease

          7. Subject must have recovered from the reversible effects of prior anti-neoplastic
             therapy, except for alopecia and ≤ grade 2 neuropathy.

          8. Subject has adequate end organ function

          9. Subject is willing to comply with all protocol-required visits, assessments, and
             procedures

         10. Male and female subjects of child-bearing potential are willing to use medically
             acceptable methods of birth control from the screening visit through 30 days after the
             last dose of study medication

        Exclusion Criteria:

          1. Subjects with documented history of tumor mutations that may not be amenable to
             treatment with RLY-1971, including:

               1. KRAS mutations: G12D, G12V, G13X, and Q61X

               2. BRAF V600E mutation

               3. MEK mutations

          2. Subjects with prior antineoplastic therapy within 3 weeks of Study Day 1, or 5
             half-lives, whichever is shorter

          3. Subjects with prior palliative radiotherapy within 1 week of Study Day 1

          4. Subjects who have had major surgery or trauma, or incomplete recovery from surgery or
             trauma, within 4 weeks of Study Day 1

          5. Subjects with known central nervous system (CNS) metastases or primary CNS tumor that
             is associated with progressive neurologic symptoms or requires increasing doses of
             corticosteroids to control the CNS disease. If patient requires corticosteroids for
             management of CNS disease, the dose must have been stable for the 2 weeks preceding
             C1D1, or subject has new lesions appearing on follow up brain MRI that require
             CNS-directed intervention.

          6. Subjects with a history or evidence of ophthalmic disease

          7. Subjects with a history or evidence of significant cardiac dysfunction

          8. Subjects with a history or evidence of significant gastrointestinal disease

          9. Subjects with other serious concurrent medical conditions

         10. Subject is pregnant, as documented by a serum beta human chorionic gonadotropin
             (β-hCG) pregnancy test consistent with pregnancy obtained within 7 days before the
             first dose of study treatment